and thyroxine (T4) into chronically hypothyroid rats were used to evaluate the contribution of intracellular T4 to T3 conversion to nuclear T3 in pituitary, liver, and kidney, and to correlate the occupancy of pituitary nuclear T3 receptors with inhibition of thyroid-stimulating hormone (TSH) release. Injection of a combination of 70 ng T3 and 400 ng T4/100 g body wt resulted in plasma T3 concentrations of 45+7 ng/dl (mean±+-SD) and 3.0±0.4,ug/dl T43 h later. At that plasma T3 level, the contribution of plasma T3 to the nuclear receptor sites resulted in saturation of 34±7% for pituitary, 27±5% for liver, and 33+2% for kidney. In addition to the T3 derived from plasma T3, there was additional T3 derived from intracellular monodeiodination of T4 in all three tissues that resulted in total nuclear occuipancy (as percent saturation) of 58±11% (pituitary), 36±8% (liver), and 41+11% (kidney), respectively. The percent contribution of T3 derived from cellular T4 added 41% of the total nuclear T3 in the pituitary which was significantly higher than the contribution of this source in the liver (24%) or the kidney (19%). 3 h after intravenous injection of increasing doses of T3, the plasma T3 concentration correlated well with both the change in TSH and the nuclear occupancy, suggesting a linear relationship between the integrated nuclear occupancy by T3 and TSH release rate. The contribution of intrapituitary T4 to T3 conversion to nuclear T, was accompanied by an appropriate decrease in TSH, supporting the biological relevance of nuclear T3. Pretreatment of the animals with 6-n-propylthiouracil before T4 injection decreased neither the nuclear T3 derived from intrapituitary T4 nor the subsequent decrease in TSH.
A B S T R A C T Inijections of triiodothyronine (T3)
and thyroxine (T4) into chronically hypothyroid rats were used to evaluate the contribution of intracellular T4 to T3 conversion to nuclear T3 in pituitary, liver, and kidney, and to correlate the occupancy of pituitary nuclear T3 receptors with inhibition of thyroid-stimulating hormone (TSH) release. Injection of a combination of 70 ng T3 and 400 ng T4/100 g body wt resulted in plasma T3 concentrations of 45+7 ng/dl (mean±+-SD) and 3.0±0. 4 ,ug/dl T43 h later. At that plasma T3 level, the contribution of plasma T3 to the nuclear receptor sites resulted in saturation of 34±7% for pituitary, 27±5% for liver, and 33+2% for kidney. In addition to the T3 derived from plasma T3, there was additional T3 derived from intracellular monodeiodination of T4 in all three tissues that resulted in total nuclear occuipancy (as percent saturation) of 58±11% (pituitary), 36±8% (liver), and 41+11% (kidney), respectively. The percent contribution of T3 derived from cellular T4 added 41% of the total nuclear T3 in the pituitary which was significantly higher than the contribution of this source in the liver (24%) or the kidney (19%). 3 h after intravenous injection of increasing doses of T3, the plasma T3 concentration correlated well with both the change in TSH and the nuclear occupancy, suggesting a linear relationship between the integrated nuclear occupancy by T3 and TSH release rate. The contribution of intrapituitary T4 to T3 conversion to nuclear T, was accompanied by an appropriate decrease in TSH, supporting the biological relevance of nuclear T3. Pretreatment of the animals with 6-n-propylthiouracil before T4 injection decreased neither the nuclear T3 derived from intrapituitary T4 nor the subsequent decrease in TSH.
These results indicate that intracellular monodeiodination of T4 contributes substantially to the nuclear T3 in the pituitary of the hypothyroid rat, and suggest a linear inverse relationship between nuclear receptor occupancy by T3 in the pituitary and TSH release rate. The data further indicate that T4 to T3 monodeiodination is considerably more important as a source of nuclear T3 in the pituitary than in the liver and kidney. This provides a mechanism whereby the TSH secretion could respond promptly to a decrease in thyroid secretion (predominantly T4) before a decrease in plasma T3 would be expected to lead to significant metabolic hypothyroidism.
INTRODUCTION
There is considerable indirect evidence suggesting that interaction of triiodothyronine (T3)l with a specific nuclear thyroid hormone receptor is a critical event in the mechanism by which thyroid hormones produce many of their effects (1) (2) (3) (4) (5) (6) (7) (8) (9) . This event has specifically been demonstrated for induction of growth hormone synthesis and inhibition of prolactin production in growth hormone (GH-1) cells and for stimulation of hepatic mitochondrial a-glycerophosphate dehydrogenase (aGPD) and malic enzyme by T3 in rats (10) (11) (12) (13) . We have recently observed (14) that there is a similar excellent chronological and quantitative correlation between nuclear occupancy by T3 and subsequent suppression of thyroid-stimulating hormone (TSH) after intravenous injection of 70 ng/100 g body wt T3 to hypothyroid rats. When 800 ng thyroxine (T4)/100 g body wt was injected, the identical TSH response was correlated with the same nuclear T3 content as after 70 ng T3/100 g body wt. Negligible quantities of T4 were found bound to the pituitary nuclei. These data suggested that nuclear occupancy by T3 may be the initial event in the process leading to the acute suppression of TSH release in hypothyroid animals after thyroid hormone administration (14) (15) (16) . Furthermore, because negligible amounts of T3 were found in the plasma during the first few hours after T4 injection, the data suggested that there was a very active conversion of T4 to T3 in the pituitary with subsequent binding of the T3 produced to the pituitary nuclei.
Because our laboratory has recently demonstrated (17) that some thyromimetic effects of T4 do not appear to be associated with appropriate increases in serum T3, the question of whether or not there is a significant quantity of intracellular T4 monodeio1ination to T3 has arisen. The T3 produced therefrom could then be bound to critical sites in the cell and produce hormone effects not manifested by an increase in the concentration of plasma T3. The present studies were performed to determine the relative quantitative importance of this source of nuclear T3 in three thyroid hormone-responsive tissues of hypothyroid rats. as estimated by affinity chromatography using specific T3 antibody coupled to Sepharose (Pharmacia Fine Chemicals, Piscataway, N. J.) by a method we recently described (18) . All injections were given to animals in a small aliquot of hypothyroid rat serum. In general, the volume of injection was <0.1 ml/lQ%1 g body wt. T4 T3 (both in free acid form) were obtained from Sigma Chemical Co. (St. Louis, Mo.). T4 was <0.5% T3 by weight as determined by radioimmunoassay (19, 20) .
METHODS
Estimation of plasma or serum T3, T4, and TSH. Plasma basal T3 concentrations were measured by radioimmunoassay (19) . The method previously used in our laboratory has been modified to use 25-,.i aliquots of rat serum or plasma.
Because of differences in nonspecific binding between rat and human serum, the standard curve included 25 ,ul of T3-free rat serum prepared using a CG-400 anion-exchange resin (Mallinckrodt Inc., St. Louis, Mo.). Plasma or serum T, was measured as described previously using human serum in the standard curve (20) . Serum TSH was assayed using reagents provided by the Pituitary Hormone Distribution Program of the National Institute of Arthritis, Metabolic, and Digestive Diseases using the modifications for tracer preparation and purification which we have recently described (15) . All other estimates of plasma or serum T3 and T4 concentrations were based on the specific activity of injected hormones (see below).
Preparation of cell nuclei. Nuclei from pituitary, hepatic, and renal tissues were prepared by centrifugation through 2.4 M sucrose, 3 mM MgCl2 (21, 22) . Before the 2.4 M sucrose centrifugation, the 1,000-g pellet was washed once with 0.32 M sucrose, 3 mM MgCl2 containing 0.5% Triton X-100. Also, the 2.4 M sucrose nuclear pellet was washed once with 0.14 M unbuffered NaCl to remove loosely bound protein. This procedure minimized the nonspecific binding and decreased the specifically bound T3 by <10% (9.5±1.0%, SD). The purity of nuclear preparations was verified by phase-contrast microscopy. In general, 2-g aliquots of liver and both kidneys were used for analyses. DNA was measured by Burton's method (23) modified by Giles and Myers (24) . The yield of pituitary nuclear DNA averaged 6+1.4 (mean +SD, n = 15) mg/g wet wt with recoveries ranging from 75 to 83%. Pituitary glands weighed from 8 to 12 mg. Hepatic nuclear DNA was 2.0±0.3 mg/g wet wt (recovery of 50±10%), and kidney nuclear DNA was 3.9±0.7 mg/g wet wt (recovery 58±10%).
Determination of the quantity of trapped plasma in pituitary tissues. The contribution of trapped plasma to tissue T3 radioactivity was negligible in agreement with previous reports (25) . In T4-injected animals, however, the contamination by plasma 125I-T4 was significant. In studies of pituitary T3 and T4 content, the trapped plasma volume was evaluated by simultaneous injection of 1311-bovine serum albumin labeled in our laboratory (14, 25) . The contribution of plasma T4 to pituitary nuclear radioactivity was shown to be eliminated by perfusion of the intact animals with 30 ml of cold saline (retrograde) through the abdominal aorta immediately after exsanguination. The plasma 125I-T4 still provided a considerable contribution to the extranuclear radioactivity. However, because the goal of the present studies was to evaluate the intracellular T3 (not T4), and this was not significantly influenced by trapped plasma, this perfusion technique was used throughout. This allowed us to inject 31I-T3 and 1251-T4 simultaneously. Our previous studies have shown that from 0 to 10% of nuclear radioactivity in the pituitary gland was T4 2-4 h after 125I-T4 administration (14) .
Specificity of nuclear thyroid hormone binding. The specificity of nuclear binding was assessed in pilot experiments. These showed that in the nuclei from pituitary, liver, and kidney, the binding of tracer T3 was decreased to <2.5% of its value by simultaneous injection of 20 ,g T3/100 g body wt.
In similar experiments performed with 125I-T4-injected animals, the pituitary nuclear radioactivity was reduced to <1.5% of the value found with tracer T4 alone by injection of 20 gg of T3. In liver and kidney, injection of 20 ,ug T3 with 125I-T4 led to a reduction of total radioactivity to 37 and 30%, respectively, of the control values, but chromatographic analysis of the nuclear radioactivity showed that this was virtually all T4, i.e., all the e25I-T3 was specifically bound to limited capacity binding sites. The '251-T4 found in the nuclear preparation under these circumstances presumably represents contamination of the nuclei with plasma and/or cytosol. Assuming that this did represent plasma contamination, it corresponded to 0.25 ,ul of plasma/mg DNA in the liver (0.52 ,tl/g wet wvt) and 0.12 ,ul/mg DNA in the kidney (0.39 ,ul/g wet wt).
Identification of labeled compounds itn nuclei, p)lasma, and injected 1251-T4. Radioactivity was extracted from nuclei using acid-butanol as previously described (14) . T3 was separated from T4 and identified by paper chromatography in tertiary amyl alcohol/hexane/2-N NH40H (6:1:5), as we have previously described (26, 27) . Nuclear radioactivity was also chromatographed in n-butanol saturated with 2 N NH40H in some studies. The locations of 1251-T3 and 1251-T4 were determined by staining unlabeled T3 and T4 (which had been added to the origin) with diazotized sulfanilic acid. 131I-T3, either injected simultaneously or added at the beginning of the extraction procedure, wvas used as an additional marker and to monitor recovery.
2-3 h after 1251-T4 injection, the plasma 125I-T4/125I-T3 ratio was very high (150-200:1). Accurate determination of the 125I-T3 present re(quired prior elimination of most of the 125I-T4 because chromatographic separation of T3 and T4 on paper generates 0.6-0.8% of the T4 as T3 (27) . Eliminilation of T4 was achieved by extracting 100 ,l of plasma with specific anti-T3 antibody conjugated to Sepharose as has been described previously (18) . In the washed Sepharose pellet, 1251-T4 was reduced to <1% of the original (jtuantity wrhile >30% of the T3 vas retained as judged by the 31I-T3 present (Appendix). The anti-T3-antibody-Sepharose conjugate was then extracted with methanol:2 N NH40H (90:10) and chromatographed on paper in tertiary amyl alcohol: hexane:2-N NH4OH as above. The contribution of artifactual T4 to T3 conversion during chromatography to the measured T3 was therefore negligible. The center of the 131I-T3 peak on paper chromatography was used for (quantitation of 1251-T3. The fraction of the original '31I-T3 present in this area wvas assessed by comparison with standards appropriately corrected for geometry and counting efficiency. The 1251-T3 originally present could then be estimated from this '31I-T3 recovery figure.
Inasmuch as the goal of the study wvas to estimate what fraction of nuclear 1251-T3 was derived from intracellular T4 to T3 conversion, that portion of nuclear '251-T3 coming from plasma had to be (juantitated and subtracted. The sources of plasma 1251-T3 were two: one was a fraction of the '25I-T3 contaminating the injected 125I-T4 still present in plasma, and the second was '251-T3 derived from intracellular monodeiodination of 1251-T4 wvhich had entered the plasma compartment.
Because 131I-T3 was injected simultaneously wvith '25I-T4, in most experiments, and because the percent contamination of each 125I-T4 tracer with T3 was knowvn, it was possible to determine the relative contribution of each of these two sources to the plasma '251-T3 present. At 2 h after injectioni of 1251-T4, >95% of the '25I-T3 wras derived from contaminlation (14) ; at 3 h, contaminlatinig '25I-T3 accounted for _40% of the plasma '251-T3. To determiinle w,hat fraction of the nuclear '25I T3 was derived from the total plasma '25I-T3, the simultaneouisly injected '31I-T3 was used to determinie the nuclear '311-T3 (counts per milligram DNA) to plasma 131I-T3 (counts per milliliter) ratio. The total plasma 125I-T3 (counts/milliliter) x 131I-T3 nuclear/plasma ratio gave the number of '251-T3 (counts per milligram DNA) present in the nucleus that was derived f'rom plasma 1251-T3. These counts were subtracted from the total nuclear '25I-T3 and the locally generated T3 was estimated as follows: nuclear '251-T3/total 1251-T4 x 2 x dose of T4 (nanograms) x 651/777) based on previous considerations (14) . A complete example of these calculations is presented in the Appendix.
Specific experimetital protocols
Assessmetnt of the maximal nluclear T3-binding capacity (MBC). MBC was measured in vivo in hypothyroid rats using an isotopic approach (3). In previous experiments it was found that from 2 h on after the injection of 70 ng T3/100 g body wt the nuclear/plasma (N/P) ratio of T3 was maximal and constant representing eqjuilibrium of T3 between receptor sites and plasma (14) . Thus, plasma T3 concentration is proportional to the concentration of T3 to which the nuclear binding sites are exposed in animals with negligible plasma T4 concentrations. Therefore, the bound T3 is in rapid exchange with the free T3 around the receptor, and between this T3 pool and plasma. This type of'equilibrium is a re(quisite f'or analysis of' the nuclear T3 content by isotopic techniqlues (28) . 3 (2) where N represents the number of unoccupied sites and NT3 the number of occupied sites or bound T3, and Kd the dissociation constant or half-maximal saturation concentration of free T3 at the receptor. Because Thus the experimental data can be fitted to a straight line with the y intercept being the MBC and the slope the halfmaximal saturation plasma concentration (29) . Further rearrangements of the above give
(5) which allows the estimation of the nuclear saturation at any plasma concentration.
Analysis of the correlations of nuclear T3 receptor occupancy and suppression of TSH release in hypothyroid rats. A plot of the plasma T3 and TSH concentrations 3 h after T3 injection and the fact that there is a short latency between thyroid hormone injection and TSH suppression (14, 15) suggested that a saturable system might be involved relating plasma T3 and the TSH release rate. If so, the data could then be fitted in the following equation as has been done for aGPD and malic enzyme (13): for all of these tissues (bar graph in Fig. 2 ). WVhen the contribution of 1251-T3 derived from local 1251-T4
tissue conversion is considered, it can be appreciated that in the pituitary it raised the nuclear saturation beyond the expected 95% confidence limits, whereas in the liver and kidney the increments were within the expected experimental variation (although by paired t test at the 70 ng T3-400 ng T4 dose this contribution was significant for both tissues (Table I) Table I it is shown that at both T3 dose levels, 1251-T4 contributed more T3 to the pituitary nuclear T3 receptors than it did in the liver and kidney (P < 0.005). Thus the degree of saturation of the pituitary nuclei was increased from 34 to 58% by injection of 400 ng/100 g body wt of T4, whereas this source of T3 only results in an increase in saturation from 27 to 36% in the liver and from 33 to 41% in the kidney. All contributions of T4 to nuclear T3 are reduced proportionately when the dose of T3
given is trebled, suggesting that the T3 derived from these two sources can mix in an intracellular compartment before binding to the nuclear receptor.
An evaluation of the N/P T3 ratios in the three tissues is presented in Table II . The pituitary N/P ratio for T3 derived from plasma alone was 0.73+0.22 but when the contribution of T3 from T4 was added, this was significantly higher, 1.03±0.26 (P < 0.005). The increase in the N/P for liver nuclei due to T3 derived from T4was also significant (P < 0.025) but modest (0.25-0.27), and there was no significant effect in the kidney.
Because the contribution of' T4 to nuclear T3 from intracellular monodeiodination is likely to be dependent on the T4 concentration within the cell, and this in turn is related to plasma T4 concentration, it was of interest to evaluate the nuclear '251-T3 to plasma '251-T4 ratio under the same circumstaniees (Table III) . This ratio, although smaller than the N/P T3 ratio by a factor of 100, is significantly higher for pituitary nuclei than it is for those of either liver or kidney at either dose of T3 given (P < 0.005). As expected, the nuclear T3/plasma T4 ratio decreased in all three tisstues when the dose of' T3 was inereased, reflectinig the limited binding capacity of the nuclear T3 receptors.
Correlation of TSH suppression wvith nu4clear and plasma T3. Severely hypothyroid rats seemed suitable models to evaluate the (quantitative relationships between ntuclear T3 and TSH stuppression because the component of' nuclear T3 dlerived from local T4 to T3 conversion is negligible. Fig. 3 shows the correlation between ATSH and ATSH/[T3] as discussed in Methods. The maximal theoretical suppression obtained 3 h after the T3 injection was 95%, and the [T3151 was 0.62 ng/ml (r = -0.91, P < 0.001).
Sources of Nuclear Triiodothyronince in Pituitary, Liver, and Kidneyl Estimated from the specific activity of the respective injected iodothyromine. Paired t test. Fig. 4 was generated by plotting the 3-h ATSH/ AMAX (i.e. the fraction of maximal attainable suppression) and nuclear T3 as a function of plasma T3. The regression lines were obtained from Eqs. 4 and 7 ( Figs. 1 and 3 Effect of the increment in nuclear T3 provided by T4 to the inhibition of pituitary TSH release. In Table IV are shown the biological effects of administration of 70 ng T3/100 g body wt with or without 400 ng/100 g body wt T4. The percent saturation of the nuclear T3 receptors by T3 from both plasma and intracellular T4 to T3 conversion is also presented. 70 ng T3 alone resulted in 32% saturation of the nuclear T3 receptors at 3 h after administration, and a 39% decrease in plasma TSH. Injection of T3-70 + T4-400 ng/100 g body wt resulted in a higher nuclear receptor occupancy of 58% (P < 0.025), with a concomitant reduction in plasma TSH equivalent to 61% ofthe basal TSH concentration (P < 0.025 compared with T3 alone). At a dosage level of 210 ng T3/100 g body wt, the nuclear T3 saturation was 60% and the decrease in plasma TSH was equivalent to 77% of the basal TSH concentration, probably reflecting a higher previous nuclear occupancy as has been discussed (14) . Addition of 400 ng T4/100 g body wt did not result in a significantly higher nuclear saturation, nor in a further decrease in plasma TSH. However, changes at this level of nuclear T3 and ATSH are more difficult to detect.
Effect of PTU pretreatment on the acute contribution of injected T4 to pituitary and hepatic nuclear T3. The results of T4 injections given to control and PTU-treated hypothyroid rats are presented in Table  V . In the pituitary, 800 ng T4/100 g body wt increased nuclear T3 0.42 ng/mg DNA. This was identical to the quantity of nuclear T3 derived from 800 ng T4/100 g body wt in PTU-pretreated rats. Thus, the lack of effect of PTU pretreatment on T4-induced TSH suppression was reflected in the absence of effect on nuclear T3 as well. Under the acute conditions of the in hypothyroid animals given the quantities of T3 depicted in Fig. 1 3 h (Fig. 1) . The results for MBC and apparent Kd in hypothyroid animals differ slightly in some tissues (liver and kidney) from those previously reported in euthyroid animals (21) , but these differences do not affect the conclusions of the present study. Because the T3 specifically bound to the nucleus either coming from plasma or from local T4 to T3 conversion can be fully displaced by an excess of cold T3, we may conclude that all the nuclear binding sites are available to both sources of T3 For reasons stated in the Introduction, we have speculated that a local mechanism for generation of T3 from T4 should be quantitatively more important as a source of nuclear T3 in the pituitary than in the liver of the rat. The results in Fig. 2 and Tables I-III indicate that when T4 is given together with T3, the increment in the pituitary nuclear T3 content is threeto fourfold that found in the liver and kidney. Tables  I-III show in detail the relative importance of this mechanism for T4 deiodination in these three tissues. Several "artifactual" explanations can be readily excluded for the presence of T3 in the nuclei of these tissues soon after T4 injection. The (uantity of locally derived T3 in the nuclei is determined from the net 1251-T3 present over that which can be accounted for by the small quantities of 1251-T3 present in plasma. Therefore, the accurate determination of plasma s25I1 T3 is quite critical. Inasmuch as the '251-T3 can be followed throughout the identification and quantitation procedure using the injected 131I-T3 (see Appendix for calculations), we are unable to postulate a mechanism by which the recoveries of the two T3 molecules, labeled with different isotopes, could be different. Because the 131I-T3 N/P ratios determined for at least pituitary and liver are quite similar to those reported by other laboratories (21), it seems unlikely that both could be underestimated. If, in some way, plasma '251-T3 were underestimated, it would result in an overestimation of' locally produced nuclear T3 from T4. This overestimation would be greatest in pituitary nuclei due to the higher N/P ratio present in this tissue in comparison with liver and kidney. It would be impossible to interpret the present experiments accurately without a precise method for specific isolation of small amounts of 1251-T3 from the large quantities of plasma 125I-T4 such as the T3-antibody-Sepharose conjugate technique used here (18) . The possibility of a rapid and disproportionately greater 1251-T4 monodeiodination (with a subsequent peak of plasma 1251_ T3) on the first passage of T4 through the tissues can also be eliminated. Because the plasma '25I-T3 derived from this reaction would disappear at the same rate as the initially injected 13'1-T3, we should have seen fivefold higher quantities of 1251-T3 than were actually observed 2-3 h after 1251-T4 injection. As the unlabeled T4 contained even less contaminating T3 than did the tracer (<l% as opposed to <0.5%), no significant physiological effect can be attributed to this source. The data demonstrating an apparently rapid rate of T4 to T3 conversion in pituitary tissue is at variance with recent in vitro studies. These have indicated that the rat kidney and liver are the most active on a weight basis (31) , and, in fact, in vitro T4 to T3 conversion has not been previously demonstrated in pituitary tissue (32) despite suggestive in vivo data in other species (33) (34) (35) (36) . However, using improved technology (18), we have recently observed T4 to T3 conversion in pituitary homogenates at rates at least similar to the rat liver on a weight basis2 under certain in vitro circumstances.
Of the total nuclear T3 in animals receiving 70 ng T3 and 400 ng T4, 41% is derived from local T4 monodeiodination in pituitary, whereas only 23 and 19% of nuclear T3, respectively, is derived from this source in liver and kidney. In rats given 210 ng T3 plus 400 ng T41100 g body wt, the relative contribution of T4 is less, but again, much higher in the pituitary than in the liver. Correspondingly, the N/P ratio for T3 after T4 is markedly higher for pituitary nuclei than it is for those of the liver and kidney. Although the biological significance of this T3 is apparent in terms of pituitary nuclei, because it is associated with TSH suppression (14 and Table IV) , there are no known rapid effects of T3 on the hepatic or renal tissues to allow early estimates of the possible physiological significance of the T3 derived from T4 in these tissues. Thus, despite the in vitro capacity of hepatic and renal tissues to produce T3 from T4, the T3 generated does not appear to contribute substantially to the nuclear T3 in these tissues.
Because the apparent affinity of nuclear receptors for T3 has been shown in vitro to be approximately the same in all tissues (21, 37), a fact we have also confirmed in vivo for the pituitary and liver in the present studies, the higher nuclear T3 content after T4 in the pituitary has to be explained on a different basis. The higher MBC of the pituitary (0.96 ng T3/mg DNA) compared to the liver (0.43 ng T3/mg DNA) cannot account for the difference either because expressing nuclear T3 derived from T4 as a percent of the MBC, i.e., in terms of saturation, the contribution of T4 to nuclear T3 in the pituitary is still significantly higher (threefold) than in the liver.
It can also be proposed that local T4 to T3 conversion and subsequent binding to the nucleus reaches equilibrium at very different intervals after T4 injection in the tissues studied. This possibility also seems unlikely because it has been estimated that 10 min are required for establishment of an equilibrium between total tissue T4 and plasma T4 in rat pituitary, liver, and kidney (25, 38) . We have found that the nuclear '251-T3/plasma 1251-T4 ratio is about 20% higher at 3 h than at 2 h after injection of 125I-T4 in both pituitary and liver suggesting that neither tissue has reached equilibrium at 3 h. Therefore, calculation of nuclear T3 from T4 at 3 h does not overestimate (but could underestimate) the contribution of this process to the nuclear T3. That this is, in fact, an underestimate is suggested by our recent results in euthyroid rats indicating that the peak of the ratio of intracellularly derived nuclear 1251-T3 to plasma '251-T4 is not attained until 16-18 h after 1251-T4 injection. 3 We have demonstrated that nuclear binding of the T3 derived from T4 to T3 conversion can be completely blocked by 20 ,tg T3/100 g body wt (14) . These results and those of the present study showing a decrease in the fraction of nuclear T3 derived fromT4 as plasma T3 concentration increases (Table I) indicate that the nuclear pools of T3 derived from both sources are miscible. We would speculate that the relative proportions of each source of T3 in the nuclei of the various tissues would be determined by the plasma concentrations of T4 and T3, the transfer rates of these hormones into the cell, the rate of intracellular T4 to T3 conversion in each tissue, and the characteristic subcellular distribution of the T3 derived from both sources in that particular tissue. The weight of each of these factors in determining the sources of nuclear T3 is not known and is currently under investigation.4 Hepatic and renal tissues have been demonstrated to be quite active in T4 monodeiodination, and yet our studies indicate that relatively small amounts of this locally produced T3 are bound to the nuclear T3 receptor. This is certainly in part influenced by the fact that <10% of total tissue T3 is found in the nucleus in these tissues, whereas more than 40% of pituitary T3 is nuclear (21) .
There is a striking correlation between plasma T3 3h after injection with the nuclear occupancy and with TSH suppression (Fig. 4) . Three facts allow us to extend this observation to say that there is an inverse linear relationship between the nuclear occupancy by T3 and the rate of TSH release. First, there is a short delay (<1 h) between nuclear occupancy by T3 and changes of TSH release rate (14, 15) . Second, because of the short half-life of TSH (30 min), decreases in TSH release rate are rapidly reflected in the plasma TSH concentration. Third, the nuclear receptor occupancy by T3 at 3 h follows closely the time of the peak nuclear occupancy, and this time is not affected by increasing T3 doses over the range used here (14, 28) . Therefore, the integrated nuclear occupancy from 0-3 h is linearly related to the nuclear occupancy at 3 h after T3 injection. These considerations provide strong support for a linear relationship between nuclear T3 receptor occupancy and the rate of TSH release and suggest that the correlation apparent in Fig. 4 is more than fortuitous.
The slight deviation to the left observed in the TSH suppression curve (Fig. 4) ([T3b10 0.62 ng/ml for TSH suppression as opposed to the [T3150 of 0.92 ng/ml for nuclear occupancy) can be accounted for by the latency between changes in nuclear occupancy and in the rate of release of TSH (14) . Thus, the plasma TSH concentration at 3 h reflects the nuclear occupancy _60 min previously. For the range of T3 doses examined, this is -20% higher at 2 than at 3 h. These data add further support to the concept that T3 effects on TSH release, like those on growth hormone stimulation and prolactin suppression in pituitary cell culJoffe, J., J. E. Silva, and P. R. Larsen. Manuscript in preparation.
Sources of Nuclear Triiodothyronine in Pituitary, Liver, and Kidney tures (5, 11) , and a-GPD and malic enzyme induction in liver tissue (12, 13) are initiated by events occurring in the nucleus. As was demonstrated in our earlier report (14) and confirmed above, the acute suppression of TSH after T4 can also be correlated with the quantity of pituitary nuclear T3, further supporting this hypothesis. However, as with the data for aGPD and malic enzyme and growth hormone stimulation and prolactin suppression, the fact that two events are correlated in time and magnitude cannot be used as evidence of causality because the.precise nature of the interrelationship between the two events is not known. As mentioned, hepatic and renal tissues are thought to be the major sources of extrathyroidal T3 production from T4. In euthyroid rats or T4-maintained hypothyroid rats, this deiodination process has been shown to be partly sensitive (-70%) to inhibition by PTU in doses similar to those used in these experiments (17, 39 (17) and confirmed in the present study. The lack of a significant decrease in hepatic nuclear T3 due to local T4 monodeiodination in acutely PTU-treated hypothyroid rats could be explained in a similar way and by the fact that the fraction of the T3 derived from T4 that binds to liver nuclei is so small. The often demonstrated inhibition of induction of hepatic aGPD associated with chronic T4 + PTU administration to hypothyroid rats is better explained by a decrease in the nuclear T3 fraction derived from plasma T3 (substantially depressed under these circumstances) than by a decrease in the nuclear T3 derived directly from intracellular T4 monodeiodination. Likewise, the small increment in TSH or in thyroid releasing hormone responsiveness observed in PTU-treated euthyroid or hypothyroid rats and man seems better explained by the demonstrated decrease in serum T3 than by inhibition of T4 to T3 conversion in the pituitary (17, (40) (41) (42) . More data are needed in euthyroid rats to exclude completely a PTU effect on intrapituitary T4 to T3 conversion under these circumstances.
If local pituitary T4 to T3 conversion is an important source of pituitary nuclear T3, if there is a linear relationship between nuclear T3 receptor occupancy and the rate of TSH release, and if in the euthyroid rat the TSH secretion rate is only =10% of the maximal attainable in hypothyroidism (15) , one must consider the possibility that in euthyroid rats, the pituitary nuclear receptor sites are saturated to a significantly greater extent than has been estimated previously (21 Fig. 2 where, using plasma T3 concentrations and the N/P T3 ratio alone, one would have estimated that pituitary nuclear receptors were only 34% saturated. The true pituitary nuclear saturation at this time was 58% due to the additional contribution of the T3 derived locally from tissue T4. This significant contribution was found in association with a plasma T4 concentration in the physiological range for the rat (3 ,ug/dl). Using techniques similar to those of the present study, we have recently estimated that pituitary nuclear receptor saturation is -78% in euthyroid rats in agreement with this hypothesis. One-half of this nuclear T3 was derived from intrapituitary T4 monodeiodination.3
The above considerations have important physiological consequences. We have shown that a decrease in saturation of nuclear binding sites is associated with an increase in the acutely suppressed plasma TSH in hypothyroid animals (14) . Presumably, a decrease in pituitary nuclear saturation due to a decrease in T3 derived locally from T4 would be similarly followed by an increased TSH release from the euthyroid pituitary. Thus, a decrease in plasma T4 alone could lead to an increase in TSH release. Our present studies suggest that the contribution of T4 to nuclear T3 in the liver and kidney is so small that significant nuclear desaturation would not occur in these tissues as a result of a modest decrease in plasma T4 alone. This could explain the circumstances in the iodine-deficient rat where an apparently euthyroid state is associated with a low plasma T4, normal plasma T3, and an elevated TSH (17, 43) . Similar arguments can be applied to explain why patients with endemic goiter, a high plasma TSH, and normal plasma T3 can appear euthyroid as well as why patients with early thyroid dysfunction with reduced plasma T4, normal plasma T3, and elevated TSH are often asvmptomatic in metabolic terms (44) (45) (46) (47) . It would appear that the presence of a system in the thyrotroph responsive to decreases in either plasma T, or T4 would provide maximum protection against the onset of metabolic hypothyroidism in tissues such as the liver and kidney whether the threat to the euthyroid state is a result of primary thyroid disease or iodine deficiency. APPENDIX A sample calculation of nuclear T3 in animals given 131I-T3 and 1251-T4 is given below. Suitable corrections for '31I appearing in the 1251 spectrometer window and changes in geometry have been performed where indicated. The nuclear T3 content was calculated based on the specific activity of injected iodothyronines as f'ollows:
Because the nuclear 1311 was >95% 31I-T3, the nuclear T3 f'rom injected T3 was: Nuclear 1311 counts 1
Total injected 1311 mg DNA x dose T3 (ng) = ng T3/mg DNA.
(1) The 125I-T3 in the nucleus was determined by paper chromatography using 1311-T3 in the nucleus as a recovery and localization standard (Methods). Nuclear '251-T3 (percent of 1251-T4 dose/mg DNA) 25I-T3 counts selected area x total nuclear 131I-T3 counts 131I-T3 counts selected area 1 100
x x mg DNA total injected 1251 To deduct from the above 1251-T3 that coming from the plasma, quantitation of the plasma '251-T3 content was required. The T3-Ab Sepharose conjugate (T3-Ab-S) was used to reduce the '251-T4 in plasma as described (14, 18 Since the N/P 1311 ratio was known, the contribution of plasma 1251-T3 to the nucleus could be determined. In the above rat, N/P 1311-T =T 3,379 (counts/10 min per nucleus) 0.054 (mg DNA) 102,420 (counts/10 min per ml) = 0.61.
The N/P for the 20 ,ug/100 g-injected rat was 0.016±0.003 (nonspecific binding). Therefore, the nuclear 1251-T3 from plasma 1251-T3 was:
(0.61 -0.016) x 0.0039%n/ml = 0.0023% dose/mg DNA. In this example, the total nuclear 125I-T3 was 0.018% dose/mg DNA. Therefore the '25I-T3 derived from local T4 monodeiodination was: 0.018 -0.0023 = 0.0157% dose/mg DNA.
To convert to nanograms T3: 
